Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1290) 1290
Publication (108) 108
Book Review (17) 17
Magazine Article (4) 4
Newsletter (3) 3
Book Chapter (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1086) 1086
index medicus (831) 831
male (809) 809
rosuvastatin (793) 793
rosuvastatin calcium (780) 780
female (710) 710
middle aged (617) 617
statins (540) 540
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (519) 519
aged (479) 479
fluorobenzenes - therapeutic use (441) 441
pyrimidines - therapeutic use (426) 426
sulfonamides - therapeutic use (424) 424
atorvastatin (410) 410
pharmacology & pharmacy (367) 367
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (366) 366
cholesterol (353) 353
treatment outcome (322) 322
cardiac & cardiovascular systems (311) 311
adult (305) 305
fluorobenzenes - adverse effects (289) 289
pyrimidines - adverse effects (280) 280
sulfonamides - adverse effects (278) 278
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (275) 275
simvastatin (253) 253
cholesterol, ldl - blood (241) 241
fluorobenzenes - administration & dosage (226) 226
pyrimidines - administration & dosage (213) 213
sulfonamides - administration & dosage (211) 211
risk factors (205) 205
risk (202) 202
pravastatin (199) 199
atorvastatin calcium (196) 196
antilipemic agents (190) 190
hypercholesterolemia - drug therapy (178) 178
cardiovascular (175) 175
drug therapy (167) 167
cardiovascular disease (163) 163
lipids (163) 163
medicine, general & internal (162) 162
prevention (158) 158
dose-response relationship, drug (154) 154
hypercholesterolemia (154) 154
atherosclerosis (153) 153
c-reactive protein (152) 152
animals (150) 150
analysis (146) 146
abridged index medicus (145) 145
double-blind method (145) 145
safety (145) 145
therapy (145) 145
coronary-heart-disease (138) 138
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (137) 137
efficacy (136) 136
statin therapy (136) 136
fluorobenzenes - pharmacology (134) 134
drug therapy, combination (133) 133
care and treatment (132) 132
dosage and administration (132) 132
heptanoic acids - therapeutic use (130) 130
pyrroles - therapeutic use (129) 129
sulfonamides - pharmacology (126) 126
pyrimidines - pharmacology (125) 125
research (125) 125
statin (125) 125
pharmacokinetics (120) 120
drug interactions (119) 119
cardiovascular diseases - prevention & control (116) 116
cardiovascular-disease (116) 116
low density lipoproteins (116) 116
prospective studies (116) 116
aged, 80 and over (115) 115
disease (112) 112
mortality (110) 110
density-lipoprotein cholesterol (109) 109
rosuvastatin calcium - therapeutic use (108) 108
anticholesteremic agents - therapeutic use (106) 106
time factors (106) 106
internal medicine (103) 103
metaanalysis (103) 103
dyslipidemias - drug therapy (101) 101
cardiovascular diseases (97) 97
clinical trials (97) 97
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (95) 95
cardiovascular agents (93) 93
health aspects (93) 93
diabetes (92) 92
hyperlipidemias - drug therapy (92) 92
rosuvastatin calcium - administration & dosage (92) 92
biomarkers - blood (91) 91
cardiology (91) 91
follow-up studies (90) 90
myocardial-infarction (90) 90
rosuvastatin calcium - adverse effects (89) 89
ezetimibe (88) 88
inflammation (88) 88
primary prevention (88) 88
randomized controlled trials as topic (88) 88
cholesterol - blood (86) 86
dyslipidemia (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1271) 1271
German (4) 4
Russian (4) 4
Spanish (4) 4
Chinese (3) 3
Italian (3) 3
Dutch (2) 2
French (2) 2
Czech (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
by Yusuf, Salim and Bosch, Jackie and Dagenais, Gilles and Zhu, Jun and Xavier, Denis and Liu, Lisheng and Pais, Prem and López-Jaramillo, Patricio and Leiter, Lawrence A and Dans, Antonio and Avezum, Alvaro and Piegas, Leopoldo S and Parkhomenko, Alexander and Keltai, Matyas and Keltai, Katalin and Sliwa, Karen and Peters, Ron J.G and Held, Claes and Chazova, Irina and Yusoff, Khalid and Lewis, Basil S and Jansky, Petr and Khunti, Kamlesh and Toff, William D and Reid, Christopher M and Varigos, John and Sanchez-Vallejo, Gregorio and McKelvie, Robert and Pogue, Janice and Jung, Hyejung and Gao, Peggy and Diaz, Rafael and Lonn, Eva and HOPE-3 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2021 - 2031
In one comparison from a 2-by-2 factorial trial, 12,705 persons at intermediate cardiovascular risk were assigned to either rosuvastatin or placebo. At 5.6... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | INTERHEART | MYOCARDIAL-INFARCTION | 52 COUNTRIES | CATARACT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - ethnology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Male | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Cholesterol | Hypertension | Myocardial infarction | Cerebral infarction | C-reactive protein | Diabetes mellitus | Cardiovascular disease | Lipids | Inflammation | Low density lipoprotein | Disease prevention | Surgery | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease
by Yusuf, Salim and Lonn, Eva and Pais, Prem and Bosch, Jackie and López-Jaramillo, Patricio and Zhu, Jun and Xavier, Denis and Avezum, Alvaro and Leiter, Lawrence A and Piegas, Leopoldo S and Parkhomenko, Alexander and Keltai, Matyas and Keltai, Katalin and Sliwa, Karen and Chazova, Irina and Peters, Ron J.G and Held, Claes and Yusoff, Khalid and Lewis, Basil S and Jansky, Petr and Khunti, Kamlesh and Toff, William D and Reid, Christopher M and Varigos, John and Accini, Jose L and McKelvie, Robert and Pogue, Janice and Jung, Hyejung and Liu, Lisheng and Diaz, Rafael and Dans, Antonio and Dagenais, Gilles and HOPE-3 Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or... 
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Perioperative Rosuvastatin in Cardiac Surgery
by Zheng, Zhe and Jayaram, Raja and Jiang, Lixin and Emberson, Jonathan and Zhao, Yan and Li, Qi and Du, Juan and Guarguagli, Silvia and Hill, Michael and Chen, Zhengming and Collins, Rory and Casadei, Barbara
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 18, pp. 1744 - 1753
Patients undergoing cardiac surgery were randomly assigned to rosuvastatin or placebo. The groups did not differ significantly in the rate of postoperative... 
C-REACTIVE PROTEIN | ENDOTHELIAL PROGENITOR CELLS | MEDICINE, GENERAL & INTERNAL | CORONARY SURGERY | REDOX STATE | CLINICAL-TRIALS | OXIDASE ACTIVITY | POSTOPERATIVE ATRIAL-FIBRILLATION | CARDIOPULMONARY BYPASS | MYOCARDIAL INJURY | RANDOMIZED CONTROLLED-TRIAL | Perioperative Care | Rosuvastatin Calcium - therapeutic use | Humans | Middle Aged | Rosuvastatin Calcium - adverse effects | Postoperative Complications - prevention & control | Male | Troponin I - blood | Cardiac Surgical Procedures | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, LDL - blood | Female | Acute Kidney Injury - chemically induced | Aged | C-Reactive Protein - analysis | Atrial Fibrillation - prevention & control | Elective Surgical Procedures | Heart | Cardiac arrhythmia | Oxidative stress | Heart attacks | Renal function | Kidneys | C-reactive protein | Heart surgery | Mortality | Clinical trials | Preventive medicine | Morbidity | Cholesterol | Troponin | Fibrillation | Troponin I | Calcium-binding protein | Surgery | Ventricle | Drug therapy | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
by Birmingham, Bruce K and Bujac, Sarah R and Elsby, Robert and Azumaya, Connie T and Wei, Cheryl and Chen, Yusong and Mosqueda-Garcia, Rogelio and Ambrose, Helen J
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2015, Volume 71, Issue 3, pp. 341 - 355
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure... 
SLCO1B1 | Pharmacogenetics | Biomedicine | Caucasian | Pharmacology/Toxicology | Pharmacokinetics | Asian | ABCG2 | WHITE | ADULT MALE-VOLUNTEERS | RISK | OATP1B1 | DISPOSITION | MARKEDLY AFFECTS | TRANSPORT | SYSTEMIC EXPOSURE | DISEASE | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Simvastatin - adverse effects | Atorvastatin Calcium - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Simvastatin - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | ATP-Binding Cassette Transporters - genetics | Adult | Female | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Atorvastatin Calcium - pharmacokinetics | European Continental Ancestry Group - genetics | Rosuvastatin Calcium - pharmacokinetics | Genotype | Simvastatin - pharmacokinetics | Simvastatin - analogs & derivatives | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Polymorphism, Single Nucleotide - genetics | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Genetic aspects | Rosuvastatin | Simvastatin | Antilipemic agents | Genotype & phenotype | Whites | Pharmacology | Statins | Asians | Polymorphism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effect of Steady‐State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open‐Label, Fixed‐Sequence Crossover Study
by Huang, Fenglei and Marzin, Kristell and Koenen, Rüdiger and Kammerer, Klaus Peter and Strelkowa, Natalja and Elgadi, Mabrouk and Quinson, Anne‐Marie and Haertter, Sebastian
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2017, Volume 57, Issue 10, pp. 1305 - 1314
Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease. It inhibits multiple cytochrome P‐450 enzymes and multiple membrane... 
faldaprevir | atorvastatin | rosuvastatin | drug–drug Interaction | COA REDUCTASE INHIBITOR | CHRONIC HEPATITIS-C | LIVER FIBROSIS | TRANSPLANT RECIPIENTS | INTERFERON-FREE | DRUG TRANSPORTERS | THERAPY | drug-drug Interaction | BI 201335 | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITOR FALDAPREVIR | Atorvastatin Calcium - analogs & derivatives | Atorvastatin Calcium - blood | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Healthy Volunteers | Oligopeptides - adverse effects | Thiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Drug Interactions | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Serine Proteinase Inhibitors - pharmacology | Atorvastatin Calcium - pharmacokinetics | Antiviral Agents - pharmacology | Rosuvastatin Calcium - pharmacokinetics | Cross-Over Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Thiazoles - pharmacology | Oligopeptides - pharmacology | Rosuvastatin | Dosage and administration | Hepatitis C | Drug therapy | Pharmacokinetics | Analysis | Metabolites | Viruses | Cytochromes | Pharmacology | Hepatitis C virus | Drug dosages | Steady state
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients
by Calza, Leonardo and Magistrelli, Eleonora and Colangeli, Vincenzo and Borderi, Marco and Contadini, Ilaria and Bon, Isabella and Re, Maria Carla and Viale, Pierluigi
AIDS, ISSN 0269-9370, 03/2017, Volume 31, Issue 5, pp. 681 - 688
BACKGROUND:Several studies have shown a significant association between vitamin D deficiency and an increased risk of statin-related symptomatic myalgia in the... 
myalgia | statin | Vitamin D | myopathy | antiretroviral therapy | C-REACTIVE PROTEIN | INFECTIOUS DISEASES | RISK-FACTORS | vitamin D | HYPERLIPIDEMIA | INTOLERANCE | IMMUNOLOGY | ATORVASTATIN | MYOSITIS-MYALGIA | VIROLOGY | PRAVASTATIN | DYSLIPIDEMIA | ROSUVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Anti-Retroviral Agents - therapeutic use | Vitamin D Deficiency - complications | Myalgia - chemically induced | Atorvastatin Calcium - administration & dosage | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Myalgia - epidemiology | Rosuvastatin Calcium - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | Aged | Retrospective Studies | Atorvastatin Calcium - adverse effects | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: potential effects on xenobiotic transporters
by Gidal, Barry E and Mintzer, Scott and Schwab, Matthias and Schutz, Ralph and Kharidia, Jahnavi and Blum, David and Grinnell, Todd and Sunkaraneni, Soujanya
Epilepsy Research, ISSN 0920-1211, 2017, Volume 135, pp. 64 - 70
Highlights • Rosuvastatin exposure was decreased (∼40%) with concomitant steady-state ESL. • The decreased rosuvastatin exposure may result from reduced oral... 
Neurology | Eslicarbazepine | Rosuvastatin | Drug interaction | Antiepileptic drugs | Epilepsy | Pharmacokinetic | ATP-DEPENDENT TRANSPORT | RISK | Pharmacoldnetic | STATINS | DISPOSITION | CLINICAL NEUROLOGY | DRUG-DRUG INTERACTION | PREMATURE MORTALITY | CANCER RESISTANCE PROTEIN | LIPIDS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Follow-Up Studies | Area Under Curve | Dibenzazepines - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Biological Availability | Male | Rosuvastatin Calcium - administration & dosage | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Anticonvulsants - adverse effects | Drug Interactions | Adult | Female | Membrane Transport Proteins - metabolism | Rosuvastatin Calcium - blood | Anticonvulsants - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Dibenzazepines - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Least-Squares Analysis | Dosage and administration | Analysis | Drug interactions | Antilipemic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Pharmacokinetic and bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium fixed-dose combination with the concomitant administration of candesartan cilexetil and rosuvastatin calcium in healthy Korean subjects
by Park, Dan-Bee and Jang, Kyungho and Lee, Jae-Won and Park, Cheol-Won and Lee, Back-Hwan and Kim, Min-Gul and Jeon, Ji-Young
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 3, pp. 286 - 294
Context: A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to... 
Rosuvastatin calcium | Candesartan cilexetil | Bioequivalence study | Angiotensin receptor blocker | Fixed-dose combination | HMG-CoA reductase | EFFICACY | rosuvastatin calcium | VOLUNTEERS | angiotensin receptor blocker | OPEN-LABEL | fixed-dose combination | STATINS | candesartan cilexetil | bioequivalence study | 2-PERIOD | PHARMACOLOGY & PHARMACY | CROSSOVER | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tablets | Area Under Curve | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Rosuvastatin Calcium - administration & dosage | Tetrazoles - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Adult | Biphenyl Compounds - blood | Benzimidazoles - adverse effects | Rosuvastatin Calcium - blood | Benzimidazoles - blood | Republic of Korea | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Biphenyl Compounds - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Benzimidazoles - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Asian Continental Ancestry Group | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Biphenyl Compounds - administration & dosage | Angiotensin II Type 1 Receptor Blockers - blood | Tetrazoles - adverse effects | Drug Combinations | Tetrazoles - pharmacokinetics | Therapeutic Equivalency | Pharmaceutical industry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Food Effect on Rosuvastatin Disposition and Low‐Density Lipoprotein Cholesterol
by McLean, Cheynne C and Teft, Wendy A and Morse, Bridget L and Gryn, Steven E and Hegele, Robert A and Kim, Richard B
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2018, Volume 104, Issue 3, pp. 525 - 533
Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and hepatic transporter‐mediated accumulation in the liver enhances its efficacy.... 
VARIABILITY | DRUG | ACID | PHARMACOKINETICS | TRANSPORTERS | HMG-COA REDUCTASE | PHARMACOLOGY & PHARMACY | PHARMACOGENETICS | PHARMACODYNAMICS | POLYMORPHISM | ATORVASTATIN | Dyslipidemias - genetics | Prospective Studies | Rosuvastatin Calcium - therapeutic use | ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism | Dyslipidemias - ethnology | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Neoplasm Proteins - metabolism | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Dyslipidemias - blood | Canada - epidemiology | Fasting - blood | Postprandial Period | Pharmacogenomic Variants | Adult | Cholesterol, LDL - blood | Female | Muscular Diseases - chemically induced | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Dyslipidemias - drug therapy | European Continental Ancestry Group - genetics | Risk Assessment | Rosuvastatin Calcium - pharmacokinetics | Down-Regulation | Food-Drug Interactions | Mice, Inbred C57BL | ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics | Treatment Outcome | Biomarkers - blood | Cross-Over Studies | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Mice | Muscular Diseases - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Rosuvastatin: Beyond the cholesterol-lowering effect
by Cortese, Annamaria and Cortese, Francesca and Gesualdo, Michele and Carbonara, Santa and Devito, Fiorella and Zito, Annapaola and Ricci, Gabriella and Scicchitano, Pietro and Ciccone, Marco Matteo
Pharmacological Research, ISSN 1043-6618, 05/2016, Volume 107, pp. 1 - 18
Abbreviations: IL-6: interleukin-6; NO: nitric oxide; LDL-C: low-density lipoprotein-cholesterol; TC: total cholesterol; VLDL: very low-density... 
Pleiotrophic effect | Cardiovascular disease | Lipid-lowering effect | Rosuvastatin | C-REACTIVE PROTEIN | CHRONIC HEART-FAILURE | COA REDUCTASE INHIBITORS | FATTY LIVER-DISEASE | LOW-DENSITY-LIPOPROTEIN | HYDROPHILIC STATIN THERAPY | HUMAN ENDOTHELIAL-CELLS | PERCUTANEOUS CORONARY INTERVENTION | ACUTE MYOCARDIAL-INFARCTION | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | Rosuvastatin Calcium - therapeutic use | Anti-Inflammatory Agents - pharmacology | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Rosuvastatin Calcium - adverse effects | Rosuvastatin Calcium - pharmacology | Antioxidants - pharmacology | Fibrinolytic Agents - adverse effects | Fibrinolytic Agents - pharmacology | Antioxidants - therapeutic use | Animals | Anti-Inflammatory Agents - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Fibrinolytic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Antioxidants - adverse effects | Enzymes | Interleukins | Low density lipoproteins | Nitric oxide | Cholesterol | Anticholesteremic agents | Antioxidants | Thiols | Analysis | Liver | Transplantation of organs, tissues, etc | Cardiovascular agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights